Evaluation of MTX-463 Administered Subcutaneously in Healthy Adult Males
Trial Parameters
Brief Summary
A randomized, double-blind, placebo-controlled, study to assess the safety, tolerability, and PK of MTX-463 when administered via SC injection in healthy adult males.
Eligibility Criteria
Inclusion Criteria: * Males aged 18 to 60 years, inclusive * Able to understand the study and provide signed, written informed consent * Able to read and understand the language of the informed consent form and other study-related materials * Willing and able to complete all protocol-required study visits and procedures * Male participants with female partners of childbearing potential must use condoms during the treatment and until 125 days after the dose of study drug. Exclusion Criteria: * Any history of clinically significant lung disease as determined by the Investigator * Any other concurrent active medical condition determined clinically significant by the Investigator * Any current skin conditions or rashes that involve the planned area of injection * Body mass index (BMI) \>30 kg/m2 * Use of any systemic immunosuppressant medications, medications to treat diabetes, antipsychotics, anticoagulants, or other medications within 90 days of Screening * Cancer or a history of cancer